Hospitals are being bought faster than patients can heal.
In 2025, the healthcare industry is in the throes of another consolidation wave. Big names are getting bigger. Regional systems are becoming national. Private equity is no longer lurking at the margins—it’s at the center of hospital boardrooms. Each acquisition, merger, or strategic partnership is marketed as a pathway to operational efficiency and better patient outcomes.
But beneath that narrative lies a harder truth: mergers and acquisitions (M&A) are reshaping healthcare around financial logic, not clinical logic—and the consequences for patient care are becoming harder to ignore.
The Financial Script: Acquisition Cost and Lifetime Value
At the heart of healthcare M&A strategy is a formula borrowed from consumer business models: cost of acquisition (CAC) versus lifetime value (LTV). These metrics guide decisions in everything from tech startups to insurance marketing. Applied to healthcare, they attempt to quantify the value of a patient across their clinical journey—how much they cost to acquire (through marketing, onboarding, or network expansion), and how much revenue they generate over time through procedures, visits, and billing codes.
It’s a neat framework. But healthcare isn’t neat.
Unlike subscription services or retail products, healthcare deals in uncertainty, urgency, and vulnerability. Patients aren’t customers. They don’t “convert” in the traditional sense. They seek care during some of the most destabilizing moments of their lives.
And yet, in acquisition spreadsheets, they are increasingly reduced to rows of actuarial data.
M&A Activity in 2025: Bigger, Bolder, Riskier
According to Kaufman Hall’s Q1 2025 M&A report, this year has already seen over 70 major hospital and system mergers, with combined valuations exceeding $65 billion. Notable transactions include:
- The merger between Atrius Health and Novant Health, creating a 300-location footprint across six states.
- A leveraged buyout of TriStar Medical Group by private equity firm Fenwick Capital, raising concerns over service-line profitability prioritization.
- The acquisition of ClearPath Oncology by a publicly traded health conglomerate, shifting oncology care from specialty clinics to consolidated cancer hubs.
While these deals claim to enhance care coordination, reduce overhead, and integrate digital systems, they often result in service line consolidation, staff reductions, and increased cost-shifting to patients.
When Clinical Judgment Meets Financial Engineering
The true cost of consolidation is not always captured on balance sheets. As providers are subsumed by larger systems, clinical autonomy often erodes. Physicians report increasing pressure to follow productivity metrics, adhere to standardized protocols dictated by revenue optimization software, or refer patients internally—even when higher-quality alternatives exist outside the system.
In a recent AMA survey, 42% of physicians in newly merged systems said they had less freedom to recommend what they believed to be the best treatment for a patient—especially when that treatment conflicted with corporate cost projections.
This is where CAC and LTV become dangerous. When healthcare decisions are filtered through spreadsheets designed to maximize revenue over time, low-margin patients—often those with complex, chronic, or underinsured conditions—are deprioritized. Procedures with favorable reimbursement profiles are promoted. And care becomes not a calling, but a transaction.
The Patient Experience: Lost in the Middle
For patients, the lived reality of consolidation is often frustratingly impersonal:
- Fewer local providers as community clinics are absorbed or shuttered.
- Longer wait times due to system-wide scheduling platforms that prioritize high-revenue services.
- Opaque billing, with facility fees tacked onto previously routine services.
- Reduced continuity, as provider turnover increases and relationship-based care becomes algorithmically distributed.
A 2025 Health Affairs study found that hospital consolidation was associated with a 6–12% increase in patient dissatisfaction scores, particularly regarding access to primary care and clarity of billing practices.
Private Equity: The Inconvenient Capital
Private equity’s growing role in M&A amplifies these concerns. While PE firms bring capital and operational expertise, their investment horizons are short (typically 3–7 years), and their goal is simple: extract maximum return.
That return often comes from aggressive cost-cutting, asset stripping, and high-margin service expansion. In behavioral health and emergency medicine, PE-backed acquisitions have been linked to staffing shortages, surprise billing, and reduced service availability—outcomes that hurt both providers and patients.
As one health system executive (speaking anonymously) told Modern Healthcare, “We don’t serve patients anymore. We serve EBITDA.”
The Policy Vacuum
Despite the rapid pace of M&A, federal and state regulators have been slow to adapt. The FTC continues to focus narrowly on antitrust issues—evaluating whether mergers reduce market competition—without adequately addressing downstream effects on care quality, equity, or cost to the patient.
Proposed reforms, such as the Hospital Merger Accountability Act and Transparency in Healthcare Consolidation Act, remain stalled in Congress, mired in bipartisan gridlock and intense lobbying pressure.
Meanwhile, insurers are consolidating too—narrowing provider networks and negotiating bulk contracts with consolidated health systems. The result is a healthcare landscape where patients have fewer choices, less transparency, and diminishing advocacy.
Reimagining Value Beyond Lifetime Revenue
It’s not enough to critique CAC and LTV. We must redefine what value means in healthcare.
Instead of measuring lifetime value by revenue, what if we measured it by long-term outcomes? Instead of focusing on cost of acquisition, what if we focused on barriers to care access? What if value was not derived from how long a patient stayed “in-network,” but how well their health was supported outside of it?
Some health systems are beginning to pilot value-based care models that attempt this reframe, linking payment to wellness outcomes rather than volume. But until the financial architecture of M&A aligns with these goals, they remain exceptions to a structurally misaligned rule.
Conclusion: Merged, but Not Healed
Mergers and acquisitions will not stop. Capital will keep flowing. Boardrooms will keep consolidating.
But unless we radically rethink the assumptions underlying those decisions, we risk constructing a healthcare system that is financially coherent—and clinically hollow.
Because in the calculus of CAC and LTV, the one metric that remains invisible is the most essential:
Whether the patient actually felt cared for.
